Hemostatic regulators of tumor angiogenesis: A source of antiangiogenic agents for cancer treatment?

Journal of the National Cancer Institute

Volumn 95, Issue 22, 2003, Pages 1660-1673

  Daly, Martina E ^a   Makris, Andreas ^c   Reed, Malcolm ^b   Lewis, Claire E ^a  

^a Academic Unit of Haematology   (United Kingdom)

^b Academic Surgical Oncology Unit   (United Kingdom)

^c MOUNT VERNON HOSPITAL   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA 2 ANTIPLASMIN; ALPHA 2 MACROGLOBULIN; ANGIOGENESIS INHIBITOR; ANGIOSTATIN; ANTINEOPLASTIC AGENT; ANTITHROMBIN; COMPLEMENTARY DNA; ENDOSTATIN; EPIDERMAL GROWTH FACTOR; FIBRIN; FIBRINOGEN; FIBRONECTIN; HEMOSTATIC AGENT; HEPARIN BINDING FIBRONECTIN; HEPARIN BINDING PROTEIN; HIGH MOLECULAR WEIGHT KININOGEN; PANCREATIC ELASTASE; PLASMINOGEN; PLASMINOGEN ACTIVATOR INHIBITOR 1; PROTHROMBIN; SCATTER FACTOR; THROMBOCYTE FACTOR 4; THROMBOSPONDIN 1; THYMIDINE KINASE; TISSUE INHIBITOR OF METALLOPROTEINASE 1; TISSUE INHIBITOR OF METALLOPROTEINASE 2; TRANSFORMING GROWTH FACTOR BETA1; TRASTUZUMAB; UNCLASSIFIED DRUG; UNINDEXED DRUG; VITRONECTIN;

ANGIOGENESIS; BLEEDING; BLOOD CLOTTING; BRAIN HEMORRHAGE; CLINICAL TRIAL; DEVELOPMENT; DRUG ACTIVITY; DRUG BLOOD LEVEL; DRUG METABOLISM; EVIDENCE BASED MEDICINE; FATIGUE; FIBRINOLYSIS; FIBROSARCOMA; HEMOSTASIS; HUMAN; INFLAMMATION; INSOMNIA; LUNG CARCINOMA; METASTASIS; NAUSEA; NONHUMAN; PRIORITY JOURNAL; REGULATORY MECHANISM; REPRODUCTION; REVIEW; SKIN INFILTRATE; THROMBOCYTE AGGREGATION; TISSUE REPAIR; TRANSIENT ISCHEMIC ATTACK; TUMOR GROWTH; TUMOR VASCULARIZATION; VIRAL GENE DELIVERY SYSTEM; WOUND HEALING;

EID: 0142112011     PISSN: 00278874     EISSN: None     Source Type: Journal    
DOI: 10.1093/jnci/djg101     Document Type: Review

References (167)

1. Broze GJ Jr. Tissue factor pathway inhibitor and the revised theory of coagulation. Annu Rev Med 1995;46:103-12.
2. Heemskerk JW, Bevers EM, Lindhout T. Platelet activation and blood coagulation. Thromb Haemost 2002;88:186-93.
3. Carmeliet P. Mechanisms of angiogenesis and arteriogenesis. Nat Med 2000;6:389-95.
4. Verheul HM, Hoekman K, Luykx-de Bakker S, Eekman CA, Folman C, Broxterman HJ, et al. Platelet: transporter of vascular endothelial growth factor. Clin Cancer Res 1997;3:2187-90.
5. Banks RE, Forbes MA, Kinsey SE, Stanley A, Ingham E, Walters C, et al. Release of the angiogenic cytokine vascular endothelial growth factor (VEGF) from platelets: significance for VEGF measurements and cancer biology. Br J Cancer 1998;77:956-64.
6. Brock TA, Dvorak HF, Senger DR. Tumor secreted vascular permeability factor increases cytosolic Ca2+ and von Willebrand factor release in human endothelial cells. Am J Pathol 1991;138:213-21.
7. Dvorak HF, Senger RD, Dvorak AM, Harvey VS, McDonagh J. Regulation of extravascular coagulation by microvascular permeability. Science 1985;227:1059-61.
8. Zucker S, Mirza H, Conner CE, Lorenz AF, Drews MH, Bahou WF, et al. Vascular endothelial growth factor induces tissue factor and matrix metalloproteinase production in endothelial cells: conversion of prothrombin to thrombin results in progelatinase-A activation and cell proliferation. Int J Cancer 1998;75:780-6.
9. Verheul HM, Jorna AS, Hoekman K, Broxterman HJ, Gebbink MF, Pinedo HM. Vascular endothelial growth factor-stimulated endothelial cells promote adhesion and activation of platelets. Blood 2000;96: 4216-21.
10. Tsopanoglou NE, Pipili-Synetos E, Maragoudakis ME. Thrombin promotes angiogenesis by a mechanism independent of fibrin formation. Am J Physiol 1993;264:C1302-7.
11. Tsopanoglou N, Maragoudakis ME. On the mechanism of thrombin-induced angiogenesis: potentiation of VEGF activity on endothelial cells by upregulation of its receptors. J Biol Chem 1999;274:23969-76.
12. Thiagarajan P, Rippon AJ, Farrell DH. Alternative adhesion sites in human fibrinogen for vascular endothelial cells. Biochemistry 1996;35: 4169-75.
13. Collen A, Koolwijk P, Kroon M, von Hinsbergh VW. Influence of fibrin structure on the formation and maintenance of capillary-like tubules by human microvascular endothelial cells. Angiogenesis 1998;2:153-66.
14. Kroon ME, Koolwijk P, van Goor H, Weidle UH, Collen A, van der Pluijm G, et al. Role and localization of urokinase receptor in the formation of new microvascular structures in fibrin matrices. Am J Pathol 1999;154:1731-42.
15. Folkman J. Tumor angiogenesis: therapeutic implications. N Engl J Med 1971;285:1182-6.
16. Folkman J. What is the evidence that tumors are angiogenesis dependent? J Natl Cancer Inst 1990;82:4-6.
17. Dvorak HF, Brown LF, Detmar M, Dvorak AM. Vascular permeability factor/vascular endothelial growth factor, microvascular hyperpermeability and angiogenesis. Am J Pathol 1995;146:1029-39.
18. Hanahan D, Christofori G, Naik P, Arbeit J. Transgenic mouse models of tumor angiogenesis: the angiogenic switch, its molecular controls, and prospects for preclinical therapeutic models. Eur J Cancer 1996;32A: 2386-93.
19. Skobe M, Rockwell P, Goldstein N, Vosseler S, Fusenig NE. Halting angiogenesis suppresses carcinoma cell invasion. Nat Med 1997;3: 1222-7.
20. 2 homeostasis. Curr Opin Genet Dev 1998;8:588-94.
21. Talks KL, Turley H, Gatter KC, Maxwell PH, Pugh CW, Ratcliffe PJ, et al. The expression and distribution of the hypoxia-inducible factors HIF-1alpha and HIF-2alpha in normal human tissues, cancers and tumor-associated macrophages. Am J Pathol 2000;157:411-21.
22. Burke B, Tang N, Corke KP, Tazzyman D, Ameri K, Wells M, et al. Expression of HIF-1alpha by human macrophages: implications for the use of macrophages in hypoxia-regulated cancer gene therapy. J Pathol 2002;196:204-12.
23. Fox SB, Gasparini G, Harris AL. Angiogenesis: pathological, prognostic, and growth-factor pathways and their link to trial design and anticancer drugs. Lancet Oncol 2001;2:278-89.
24. Lip GY, Chin BS, Blann AD. Cancer and the prothrombotic state. Lancet Oncol 2002;3:27-34.
25. Chen J, Bierhaus A, Schiekoker S, Andrassy M, Chen B, Stern DM, et al. Tissue factor-a receptor involved in the control of cellular properties, including angiogenesis. Thromb Haemost 2001;86:334-45.
26. Falanga A, Gordon SG. Isolation and characterization of cancer procoagulant: a cysteine proteinase from malignant tissue. Biochemistry 1985;24:5558-67.
27. Lorenzet R, Donati MB. Blood clotting activation, angiogenesis and tumor metastasis: any role for TFPI? Thromb Haemost 2002;87:928-9.
28. Gasic GJ, Gasic TB, Stewart CC. Antimetastatic effects associated with platelet reduction. Proc Natl Acad Sci U S A 1968;61:46-52.
29. Pinedo HM, Verheul HM, D'Amato RJ, Folkman J. Involvement of platelets in tumour angiogenesis? Lancet 1998;352:1775-7.
30. Verheul HM, Hoekman K, Lupu F, Broxterman HJ, van der Valk P, Kakkar AK, et al. Platelet and coagulation activation with vascular endothelial growth factor generation in soft tissue sarcomas. Clin Cancer Res 2000;6:166-71.
31. O'Reilly MS, Holmgren L, Shing Y, Chen C, Rosenthal RA, Moses M, et al. Angiostatin: a novel angiogenesis inhibitor that mediates the suppression of metastases by a Lewis lung carcinoma. Cell 1994;79:315-28.
32. Cao Y, Ji RW, Davidson D, Schaller J, Marti D, Söhndel S, et al. Kringle domains of human angiostatin. Characterization of the anti-proliferative activity on endothelial cells. J Biol Chem 1996;271:29461-7.
33. Kwon M, Yoon CS, Fitzpatrick S, Kassam G, Graham KS, Young MK, et al. p22 is a novel plasminogen fragment with anti-angiogenic activity. Biochemistry 2001;40:13246-53.
34. Dong Z, Kuma R, Yang X, Fidler IJ. Macrophage-derived metalloelastase is responsible for the generation of angiostatin in Lewis lung carcinoma. Cell 1997;88:801-10.
35. Lijnen HR, Ugwu F, Bini A, Collen D. Generation of an angiostatin-like fragment from plasminogen by stromelysin-1 (MMP-3). Biochemistry 1998;37:4699-702.
36. Patterson BC, Sang QA. Angiostatin-converting enzyme activities of human matrilysin (MMP-7) and gelatinase B/type IV collagenase (MMP-9). J Biol Chem 1997;272:28823-5.
37. Stathakis P, Fitzgerald M, Matthias LJ, Chesterman CN, Hogg PF. Generation of angiostatin by reduction and proteolysis of plasmin. Catalysis by a plasmin reductase secreted by cultured cells. J Biol Chem 1997;272: 20641-5.
38. Gately S, Twardowski P, Stack MS, Cundiff DL, Grella D, Castellino FJ, et al. The mechanism of cancer-mediated conversion of plasminogen to the angiogenesis inhibitor angiostatin. Proc Natl Acad Sci U S A 1997; 94:10868-72.
39. O'Reilly MS, Wiederschain D, Stetler-Stevenson WG, Folkman J, Moses MA. Regulation of angiostatin production by matrix metalloproteinase-2 in a model of concomitant resistance. J Biol Chem 1999;274:29568-71.
40. Claesson-Welsh L, Welsh M, Ito N, Anand-Apte B, Soker S, Zetter B, et al. Angiostatin induces endothelial cell apoptosis and activation of focal adhesion kinase independently of the integrin-binding motif RGD. Proc Natl Acad Sci U S A 1998;95:5579-83.
41. Ji WR, Castellino FJ, Chang Y, Deford ME, Gray H, Villarreal X, et al. Characterization of kringle domains of angiostatin as antagonists of endothelial cell migration, an important process in angiogenesis. FASEB J 1998;12:1731-8.
42. Stack MS, Gately S, Bafetti LM, Enghild JJ, Soff GA. Angiostatin inhibits endothelial and melanoma cellular invasion by blocking matrix-enhanced plasminogen activation. Biochem J 1999;340:77-84.
43. Moser TL, Kenan DJ, Ashley TA, Roy JA, Goodman MD, Misra UK, et al. Endothelial cell surface F1-F0 ATP synthase is active in ATP synthesis and is inhibited by angiostatin. Proc Natl Acad Sci U S A 2001;98:6656-61.
44. Troyanovsky B, Levchenko T, Manson G, Matvijenko O, Holmgren L. Angiomotin: an angiostatin binding protein that regulates endothelial cell migration and tube formation. J Cell Biol 2001;152:1247-54.
45. Sim BK, MacDonald NJ, Gubish ER. Angiostatin and endostatin: endogenous inhibitors of tumor growth. Cancer Metastasis Rev 2000; 19:181-90.
46. Cao Y, O'Reilly MS, Marshall B, Flynn E, Ji RW, Folkman J. Expression of angiostatin cDNA in a murine fibrosarcoma suppresses primary tumor growth and produces long-term dormancy of metastases. J Clin Invest 1998;101:1055-63.
47. Fukumori T, Nishitani M, Naroda T, Onishi T, Oka N, Kanayama H, et al. Expression of angiostatin cDNA in a murine renal cell carcinoma suppresses tumor growth in vivo. Urology 2002;59:973-7.
48. Tanaka T, Cao Y, Folkman J, Fine HA. Viral vector-targeted antiangiogenic gene therapy utilizing an angiostatin complementary DNA. Cancer Res 1998;58:3362-9.
49. Ma HI, Lin SZ, Chiang YH, Li J, Chen SL, Tsao YP, et al. Intratumoral gene therapy of malignant brain tumor in a rat model with angiostatin delivered by adeno-associated viral (AAV) vector. Gene Ther 2002;9: 2-11.
50. Sacco MG, Caniatti M, Cato EM, Frattini A, Chiesa G, Ceruti R, et al. Liposome-delivered angiostatin strongly inhibits tumor growth and metastatization in a transgenic model of spontaneous breast cancer. Cancer Res 2000;60:2660-5.
51. Matsumoto G, Sasakuri K, Tsukinoki K, Ohmi Y, Lee U, Shindo J. Growth of human squamous cell carcinoma xenografts in mice is inhibited by local angiostatin gene therapy. Oral Oncol 2002;38:543-8.
52. Matsuda KM, Madoiwa S, Hasumi Y, Kanazawa T, Saga Y, Kume A, et al. A novel strategy for the tumor angiogenesis-targeted gene therapy: generation of angiostatin from endogenous plasminogen by protease gene transfer. Cancer Gene Ther 2000;7:589-96.
53. Gorski DH, Mauceri HJ, Salloum RM, Gately S, Hellman S, Beckett MA, et al. Potentiation of the antitumor effect of ionising radiation by brief concomitant exposures to angiostatin. Cancer Res 1998;58:5686-9.
54. Calnek DS, Grinnell BW. Thrombomodulin-dependent anticoagulant activity is regulated by vascular endothelial growth factor. Exp Cell Res 1998;238:294-8.
55. Esmon CT. Regulation of blood coagulation. Biochim Biophys Acta 2000;1477:349-60.
56. Mann KG. Prothrombin. Methods Enzymol 1976;45:123-56.
57. Taneda H, Andoh K, Nishioka J, Takeya H, Suzuki K. Blood coagulation factor Xa interacts with a linear sequence of the kringle 2 domain of prothrombin. J Biochem (Tokyo) 1994;116:589-97.
58. Deguchi H, Takeya H, Gabazza EC, Nishioka J, Suzuki K. Prothrombin kringle 1 domain interacts with factor Va during the assembly of prothrombinase complex. Biochem J 1997;321:729-35.
59. Lee TH, Rhim TY, Kim SS. Prothrombin kringle-2 domain has a growth inhibitory activity against basic fibroblast growth factor-stimulated capillary endothelial cells. J Biol Chem 1998;273:28805-12.
60. Rhim TY, Park CS, Kim E, Kim SS. Human prothrombin fragment 1 and 2 inhibit bFGF-induced BCE cell growth. Biochem Biophys Res Commun 1998;252:513-6.
61. Kim B, Koo S, Kim S. A peptide derived from human prothrombin fragment 2 inhibits prothrombinase and angiogenesis. Thromb Res 2002; 106:81-7.
62. O'Reilly MS, Pirie-Shepherd S, Lane WS, Folkman J. Anti-angiogenic activity of the cleaved conformation of the serpin antithrombin. Science 1999;285:1926-8.
63. Rosenberg RD, Damus PS. The purification and mechanism of action of human antithrombin-heparin cofactor. J Biol Chem 1973;248:6490-505.
64. Wright HT, Scarsdale JN. Structural basis for serpin inhibitor activity. Proteins 1995;22:210-25.
65. Carrell RW, Huntington JA, Mushunje A, Zhou A. The conformational basis of thrombosis. Thromb Haemost 2001;86:14-22.
66. Marcum JA, Rosenberg RD. Anticoagulantly active heparin-like molecules from vascular tissue. Biochemistry 1984;23:1730-7.
67. Wardell MR, Chang WS, Bruce D, Skinner R, Lesk AM, Carrell RW. Preparative induction and characterization of L-antithrombin: a structural homologue of latent plasminogen activator inhibitor-1. Biochemistry 1997;36:13133-42.
68. Larsson H, Akerud P, Nordling K, Raub-Segall E, Claesson-Welsh L, Bjork I. A novel anti-angiogenic form of antithrombin with retained proteinase binding ability and heparin affinity. J Biol Chem 2001;276: 11996-2002.
69. Larsson H, Sjöblom T, Dixelius J, Östman A, Ylinenjärvi K, Björk I, et al. Anti-angiogenic effects of latent antithrombin through perturbed cell-matrix interactions and apoptosis of endothelial cells. Cancer Res 2000; 60:6723-9.
70. Zhang M, Volpert O, Shi YH, Bouck N. Maspin is an angiogenesis inhibitor. Nat Med 2000;6:196-9.
71. Dawson DW, Volpert OV, Gillis P, Crawford SE, Xu H, Benedict W, et al. Pigment epithelium-derived factor: a potent inhibitor of angiogenesis. Science 1999;285:245-8.
72. Célérier J, Cruz A, Lamandé N, Gasc JM, Corvol P. Angiotensinogen and its cleaved derivatives inhibit angiogenesis. Hypertension 2002;39: 224-8.
73. Bootle-Wilbraham CA, Tazzyman S, Marshall JM, Lewis CE. Fibrinogen E-fragment inhibits the migration and tubule formation of human dermal microvascular endothelial cells in vitro. Cancer Res 2000;60:4719-24.
74. Brown NJ, Staton CA, Rodgers GR, Corke KP, Underwood JC, Lewis CE. Fibrinogen E fragment selectively disrupts the vasculature and inhibits the growth of murine tumours in a syngeneic murine model. Br J Cancer 2002;86:1813-6.
75. Bootle-Wilbraham CA, Tazzyman S, Thompson WD, Stirk CM, Lewis CE. Fibrin fragment E stimulates the proliferation, migration and differentiation of human microvascular endothelial cells in vitro. Angiogenesis 2001;4:269-75.
76. Thompson WD, Smith E, Stirk CM, Marshall F, Stout AJ, Kocchar A. Angiogenic activity of fibrin degradation products is located in fibrin fragment E. J Pathol 1992;168:47-53.
77. Adams JC. Thrombospondins: multifunctional regulators of cell interactions. Annu Rev Cell Dev Biol 2001;17:25-51.
78. De Fraipont F, Nicholson AC, Feige JJ, Van Meir EG. Thrombospondins and tumor angiogenesis. Trends Mol Med 2001;7:401-7.
79. Murphy-Ullrich JE, Poczatek M. Activation of latent TGF-beta by thrombospondin-1: mechanisms and physiology. Cytokine Growth Factor Rev 2000;11:59-69.
80. Schultz-Cherry S, Ribeiro S, Gentry L, Murphy-Ullrich JE. Thrombospondin binds and activates the small and large forms of latent transforming growth factor-beta in a chemically defined system. J Biol Chem 1994;269:26775-82.
81. Pepper MS. Transforming growth factor-beta: vasculogenesis, angiogenesis, and vessel wall integrity. Cytokine Growth Factor Rev 1997; 8:21-43.
82. Good DJ, Polverini PJ, Rastinejad F, Le Beau MM, Lemons RS, Frazier WA, et al. A tumor suppressor-dependent inhibitor of angiogenesis is immunologically and functionally indistinguishable from a fragment of thrombospondin. Proc Natl Acad Sci U S A 1990;87:6624-8.
83. Taraboletti G, Roberts D, Liotta LA, Giavazzi R. Platelet thrombospondin modulates endothelial cell adhesion, motility, and growth: a potential angiogenesis regulatory factor. J Cell Biol 1990;111:765-72.
84. Tolsma SS, Volpert OV, Good DJ, Frazier WA, Polverini PJ, Bouck N. Peptides derived from two separate domains of the matrix protein thrombospondin-1 have anti-angiogenic activity. J Cell Biol 1993;122: 497-511.
85. Iruela-Arispe ML, Lombardo M, Krutzsch HC, Lawler J, Roberts DD. Inhibition of angiogenesis by thrombospondin-1 is mediated by 2 independent regions within the type 1 repeats. Circulation 1999;100:1423-31.
86. Jimenez B, Volpert OV, Crawford SE, Febbraio M, Silverstein RL, Bouck N. Signals leading to apoptosis-dependent inhibition of neovascularization by thrombospondin-1. Nat Med 2000;6:41-8.
87. Nicosia RF, Tuszynski GP. Matrix-bound thrombospondin promotes angiogenesis in vitro. J Cell Biol 1994;124:183-93.
88. Taraboletti G, Morbidelli L, Donnini S, Parenti A, Granger HJ, Giavazzi R, et al. The heparin binding 25kDa fragment of thrombospondin-1 promotes angiogenesis and modulates gelatinase and TIMP-2 production in endothelial cells. FASEB J 2000;14:1674-6.
89. Tang B, Bottinger EP, Jakowlew SB, Bagnall KM, Mariano J, Anver MR, et al. Transforming growth factor-beta1 is a new form of tumor suppressor with true haploid insufficiency. Nat Med 1998;4:802-7.
90. Factor VM, Kao CY, Santoni-Rugiu E, Woitach JT, Jensen MR, Thorgeirsson SS. Constitutive expression of mature transforming growth factor beta1 in the liver accelerates hepatocarcinogenesis in transgenic mice. Cancer Res 1997;57:2089-95.
91. Taylor S, Folkman J. Protamine is an inhibitor of angiogenesis. Nature 1982;297:307-12.
92. Maione TE, Gray GS, Petro J, Hunt AJ, Donner AL, Bauer SI, et al. Inhibition of angiogenesis by recombinant human platelet factor-4 and related peptides. Science 1990;247:77-9.
93. Maione TE, Gray GS, Hunt AJ, Sharpe RJ. Inhibition of tumor growth in mice by an analogue of platelet factor 4 that lacks affinity for heparin and retains potent angiostatic activity. Cancer Res 1991;51:2077-83.
94. Gengrinovitch S, Greenberg SM, Cohen T, Gitay-Goren H, Rockwell P, Maione TE, et al. Platelet factor-4 inhibits the mitogenic activity of VEGF121 and VEGF165 using several concurrent mechanisms. J Biol Chem 1995;270:15059-65.
95. Sulpice E, Bryckaert M, Lacour J, Contreres JO, Tobelem G. Platelet factor 4 inhibits FGF2-induced endothelial cell proliferation via the extracellular signal-regulated kinase pathway but not by the phosphatidylinositol-3-kinase pathway. Blood 2002;100:3087-94.
96. Hu GF, Strydom DJ, Fett JW, Riordan JF, Vallee BL. Actin is a binding protein for angiogenin. Proc Natl Acad Sci U S A 1993;90:1217-21.
97. Gentilini G, Kirschbaum NE, Augustine JA, Aster RH, Visentin GP. Inhibition of human umbilical vein endothelial cell proliferation by the CXC chemokine, platelet factor 4 (PF4), is associated with impaired downregulation of p21(Cip1/WAF1). Blood 1999;93:25-33.
98. Sharpe RJ, Byers HR, Scott CF, Bauer SI, Maione TE. Growth inhibition of murine melanoma and human colon carcinoma by recombinant human platelet factor-4. J Natl Cancer Inst 1990;82:848-53.
99. Kolber DL, Knisely TL, Maione TE. Inhibition of development of murine melanoma lung metastases by systemic administration of recombinant platelet factor 4. J Natl Cancer Inst 1995;87:304-9.
100. Tanaka T, Manome Y, Wen P, Kufe DW, Fine HA. Viral vector-mediated transduction of a modified platelet factor 4 cDNA inhibits angiogenesis and tumor growth. Nat Med 1997;3:437-42.
101. Hampl M, Tanaka T, Albert PS, Lee J, Ferrari N, Fine HA. Therapeutic effects of viral vector-mediated anti-angiogenic gene transfer in malignant ascites. Hum Gene Ther 2001;12:1713-29.
102. Jouan V, Canron X, Alemany M, Caen JP, Quentin G, Plouet J, et al. Inhibition of in vitro angiogenesis by platelet factor-4-derived peptides and mechanism of action. Blood 1999;94:984-93.
103. Hagedorn M, Zilberberg L, Lozano RM, Cuevas P, Canron X, Redondo Horcajo M, et al. A short peptide domain of platelet factor 4 blocks angiogenic key events induced by FGF-2. FASEB J 2001;15:550-2.
104. Murate T, Yamashita K, Isogai C, Suzuki H, Ichihara M, Hatano S, et al. The production of tissue inhibitors of metalloproteinases (TIMPs) in megakaryopoiesis: possible role of platelet- and megakaryocyte-derived TIMPs in bone marrow fibrosis. Br J Haematol 1997;99:181-9.
105. Fay WP, Shapiro AD, Shih JL, Schleef RR, Ginsburg D. Brief report: complete deficiency of plasminogen-activator inhibitor type 1 due to a frame-shift mutation. N Engl J Med 1992;327:1729-33.
106. Carmeliet P, Stassen JM, Schoonjans L, Ream B, van den Oord JJ, De Mol M, et al. Plasminogen activator inhibitor-1 gene-deficient mice. II. Effects on haemostasis, thrombosis, and thrombolysis. J Clin Invest 1993;92:2756-60.
107. Hill SA, Shaughnessy SG, Joshua P, Ribau J, Austin RC, Podor TJ. Differential mechanisms targeting type 1 plasminogen activator inhibitor and vitronectin into the storage granules of a human megakaryocytic cell line. Blood 1996;87:5061-73.
108. Stefansson S, Lawrence DA. The serpin PAI-1 inhibits cell migration by blocking integrin alpha V beta 3 binding to vitronectin. Nature 1996;383: 441-3.
109. Stefansson S, Petitclerc E, Wong MK, McMahon GA, Brooks PC, Lawrence DA. Inhibition of angiogenesis in vivo by plasminogen activator inhibitor-1. J Biol Chem 2001;276:8135-41.
110. Harbeck N, Schmitt M, Kates RE, Kiechle M, Zemzoum I, Janicke F, et al. Clinical utility of urokinase-type plasminogen activator and plasminogen activator inhibitor-1 determination in primary breast cancer tissue for individualized therapy concepts. Clin Breast Cancer 2002;3:196-200.
111. Gemma A, Takenaka K, Hosoya Y, Matuda K, Seike M, Kurimoto F, et al. Altered expression of several genes in highly metastatic subpopulations of a human pulmonary adenocarcinoma cell line. Eur J Cancer 2001;37:1554-61.
112. Taponeco F, Curcio C, Giuntini A, Nardini V, Fornaciari G, Artini PG, et al. Expression and prognostic significance of urokinase and plasminogen activator inhibitor type-1 in endometrial hyperplasia and cancer. J Exp Clin Cancer Res 2001;20:239-46.
113. Devy L, Blacher S, Grignet-Debrus C, Bajou K, Masson V, Gerard RD, et al. The pro- or anti-angiogenic effect of plasminogen activator inhibitor 1 is dose dependent. FASEB J 2002;16:147-54.
114. McMahon G, Petitclerc E, Stefansson S, Smith E, Wong MK, Westrick RJ, et al. Plasminogen activator inhibitor-1 regulates tumor growth and angiogenesis. J Biol Chem 2001;276:33964-8.
115. Kim I, Kim HG, Moon SO, Chae SW, So JN, Koh KN, et al. Angiopoietin-1 induces endothelial cell sprouting through the activation of focal adhesion kinase and plasmin secretion. Circ Res 2000;86:952-9.
116. Soker S, Svahn CM, Neufeld G. Vascular endothelial growth factor is inactivated by binding to alpha 2-macroglobulin and the binding is inhibited by heparin. J Biol Chem 1993;268:7685-91.
117. Asplin IR, Wu SM, Mathew S, Bhattacharjee G, Pizzo SV. Differential regulation of the fibroblast growth factor (FGF) family by alpha(2)-macroglobulin: evidence for selective modulation of FGF-2-induced angiogenesis. Blood 2001;97:3450-7.
118. O'Reilly MS, Boehm T, Shing Y, Fukai N, Vasios G, Lane WS, et al. Endostatin: an endogenous inhibitor of angiogenesis and tumor growth. Cell 1997;88:277-85.
119. Miosge N, Sasaki T, Timpl R. Angiogenesis inhibitor endostatin is a distinct component of elastic fibers in vessel walls. FASEB J 1999;13: 1743-50.
120. Ma L, Elliott SN, Cirino G, Buret A, Ignarro LJ, Wallace JL. Platelets modulate gastric ulcer healing: role of endostatin and vascular endothelial growth factor release. Proc Natl Acad Sci U S A 2001;98:6470-5.
121. Ma L, Hollenberg MD, Wallace JL. Thrombin-induced platelet endostatin release is blocked by a proteinase activated receptor-4 (PAR4) antagonist. Br J Pharmacol 2001;134:701-4.
122. Nelson J, Allen WE, Scott WN, Bailie JR, Walker B, McFerran NV, et al. Murine epidermal growth factor (EGF) fragment (33-42) inhibits both EGF- and laminin-dependent endothelial cell motility and angiogenesis. Cancer Res 1995;55:3772-6.
123. Homandberg GA, Williams JE, Grant D, Schumacher B, Eisenstain R. Heparin-binding fragments of fibronectin are potent inhibitors of endothelial cell growth. Am J Pathol 1985;120:327-32.
124. Colman RW, Schmaier AH. Contact system: a vascular biology modulator with anticoagulant, profibrinolytic, antiadhesive, and proinflammatory attributes. Blood 1997;90:3819-43.
125. Weisel JW, Nagaswami C, Woodhead JL, DeLa Cadena RA, Page JD, Colman RW. The shape of high molecular weight kininogen: organization into structural domains, changes with activation, and interactions with prekallikrein, as determined by electron microscopy. J Biol Chem 1994; 269:10100-6.
126. Colman RW, Jameson BA, Lin Y, Johnson D, Mousa SA. Domain 5 of high molecular weight kininogen (kininostatin) down-regulates endothelial cell proliferation and migration and inhibits angiogenesis. Blood 2000;95:543-50.
127. Zhang JC, Claffey K, Sakthivel R, Darzynkiewicz Z, Shaw DE, Leal J, et al. Two-chain high molecular weight kininogen induces endothelial cell apoptosis and inhibits angiogenesis: partial activity within domain 5. FASEB J 2000;14:2589-600.
128. Guo YL, Wang S, Colman RW. Kininostatin, an angiogenic inhibitor, inhibits proliferation and induces apoptosis of human endothelial cells. Arterioscler Thromb Vasc Biol 2001;21:1427-33.
129. Zhang JC, Donate F, Qi X, Ziats NP, Juarez JC, Mazar AP, et al. The anti-angiogenic activity of cleaved high molecular weight kininogen is mediated through binding to endothelial cell tropomyosin. Proc Natl Acad Sci U S A 2002;99:12224-9.
130. Boehm T, Folkman J, Browder T, O'Reilly MS. Anti-angiogenic therapy of experimental cancer does not induce acquired drug resistance. Nature 1997;390:404-7.
131. Kerbel RS, Viloria-Petit A, Klement G, Rak J. 'Accidental' antiangiogenic drugs. Anti-oncogene directed signal transduction inhibitors and conventional chemotherapeutic agents as examples. Eur J Cancer 2000;36:1248-57.
132. Voest EE, Beerepoot LV, Groenewegen G, Fogler WE, Sim BK, Sidor C, et al. Phase I trial of recombinant human angiostatin by twice-daily subcutaneous injection in patients with advanced cancer [abstract 322]. Proc ASCO 2002;21:81a.
133. Eder JP Jr, Supko JG, Clark JW, Puchalski TA, Garcia-Carbonero R, Ryan DP, et al. Phase I clinical trial of recombinant human endostatin administered as a short intravenous infusion repeated daily. J Clin Oncol 2002;20:3772-84.
134. Eder JP, Clark J, Supko J, Garcia-Carboreo R, Ryan DP, Shulman L, et al. A phase I trial of recombinant human endostatin [abstract 323]. Proc ASCO 2002;21:81a.
135. Herbst RS, Hess KR, Tran HT, Tseng JE, Mullani NA, Charnsangavej C, et al. Phase I study of recombinant human endostatin in patients with advanced solid tumors. J Clin Oncol 2002;20:3792-803.
136. Herbst RS, Mullani NA, Davis DW, Hess KR, McConkey DJ, Charnsangavej C, et al. Development of biologic markers of response and assessment of anti-angiogenic activity in a clinical trial of human recombinant endostatin. J Clin Oncol 2002;20:3804-14.
137. Reiher FK, Volpert OV, Jimenez B, Crawford SE, Dinney CP, Henkin J, et al. Inhibition of tumor growth by systemic treatment with thrombospondin-1 peptide mimetics. Int J Cancer 2002;98:682-9.
138. de Vos FY, Hoekstra R, Gietema JA, Jager PJ, Eskens FA, Carr R, et al. A phase I dose escalating study of the angiogenesis inhibitor thrombospondin-mimetic (ABT-510) in patients with advanced cancer [abstract 248]. Eur J Cancer 2002;38:78.
139. Duffy MJ, Reilly D, O'Sullivan C, O'Higgins N, Fennelly JJ, Andreasen P. Urokinase-plasminogen activator, a new and independent prognostic marker in breast cancer. Cancer Res 1990;50:6827-9.
140. Evans DM, Lin PL. Suppression of pulmonary metastases of rat mammary cancer by recombinant urokinase plasminogen activator inhibitor. Am Surg 1995;61:692-6.
141. Bartz R, Ullrich S, Schmalix WA, Knoeller J, Wilhelm OG, Wilex AG. First dose in man phase I study of the anti-metastatic uPA inhibitor WX-UK1 [abstract 238]. Eur J Cancer 2002;38:75.
142. Dvorak HF. Vascular permeability factor/vascular endothelial growth factor: a critical cytokine in tumor angiogenesis and a potential target for diagnosis and therapy. J Clin Oncol 2002;20:4368-80.
143. Brekken RA, Overholser JP, Stastny VA, Waltenberger J, Minna JD, Thorpe PE. Selective inhibition of vascular endothelial growth factor (VEGF) receptor 2 (KDR/Flk-1) activity by a monoclonal anti-VEGF antibody blocks tumor growth in mice. Cancer Res 2000;60:5117-24.
144. Shaheen RM, Davis DW, Liu W, Zebrowski BK, Wilson MR, Bucana CD, et al. Anti-angiogenic therapy targeting the tyrosine kinase receptor for vascular endothelial growth factor receptor inhibits the growth of colon cancer liver metastasis and induces tumor and endothelial cell apoptosis. Cancer Res 1999;59:5412-6.
145. Gordon MS, Margolin K, Talpaz M, Sledge GW, Holmgren E, Benjamin R, et al. Phase I safety and pharmacokinetic study of recombinant human anti-vascular endothelial growth factor in patients with advanced cancer. J Clin Oncol 2001;19:843-50.
146. Margolin K, Gordon MS, Holmgren E, Gaudreault J, Novotny W, Fyfe G, et al. Phase Ib trial of intravenous recombinant humanized monoclonal antibody to vascular endothelial growth factor in combination with chemotherapy in patients with advanced cancer: pharmacologic and long-term safety data. J Clin Oncol 2001;19:851-6.
147. Bergsland E, Hurwitz H, Fehrenbacher L, Meropol N, Novotny W, Gaudreault J, et al. A randomized phase II trial comparing rhuMAb VEGF (recombinant humanized monoclonal antibody to vascular endothelial cell growth factor) plus 5-fluorouracil/leucovorin (FU/LV) to FU/LV alone in patients with metastatic colorectal cancer [abstract 939]. Proc ASCO 2000;19:242a.
148. Sledge G, Miller K, Novotny WF, Gaudreault J, Ash M, Cobleigh M. A phase II trial of single agent rhuMab VEGF (recombinant humanized monoclonal antibody to vascular endothelial growth factor) in patients with relapsed metastatic breast cancer [abstract 5c]. Proc ASCO 2000;19:3a.
149. DeVore R, Fehrenbacher L, Herbst R, Langer C, Kelly K, Gaudreault J, et al. A randomized phase II trial comparing rhumab VEGF (recombinant humanized monoclonal antibody to vascular endothelial growth factor) plus carboplatin/paclitaxel (CP) to CP alone in patients with stage IIIb/IV NSCLC [abstract 1896]. Proc ASCO 2000;19:458a.
150. Yang JC, Haworth L, Steinberg SM, Rosenberg SA, Novotny W. A randomized double-blind placebo-controlled trial of bevacizumab (anti-VEGF antibody) demonstrating a prolongation in time to progression in patients with metastatic renal cancer [abstract 15]. Proc ASCO 2002;21:5a.
151. Hurwitz H, Fehrenbacher L, Cartwright T, Hainsworth J, Heim W, Berlin J, et al. Bevacizumab (a monoclonal antibody to vascular endothelial growth factor) prolongs survival in first-line colorectal cancer (CRC): results of a phase III trial of bevacizumab in combination with bolus IFL (irinotecan, 5-fluorouracil, leucovorin) as first-line therapy in subjects with metastatic CRC [abstract 3646]. Proc ASCO 2003;22.
152. Fong TA, Shawver LK, Sun L, Tang C, App H, Powell TJ, et al. SU5416 is a potent and selective inhibitor of the vascular endothelial growth factor receptor (Flk1/KDR) that inhibits tyrosine kinase catalysis, tumor vascularization, and growth of multiple tumor types. Cancer Res 1999;59:99-106.
153. Cropp GF, Hanna AL. SU5416, a molecularly targeted novel antiangiogenesis drug: clinical pharmacokinetics and safety review. Proc 11th NCI-EORTC-AACR Symposium on New Drugs in Cancer Therapy. Clin Cancer Res 2000;6(Suppl):Abstract 262.
154. Rosen P, Amado R, Hecht J, Chang D, Mulay M, Parson M, et al. A phase I/II study of SU5416 in combination with 5FU/leucovorin in patients with metastatic colorectal cancer [abstract 5d]. Proc ASCO 2000;19:3a.
155. Rothenberg M, Berlin J, Cropp G, Fleischer AC, Schumaker RD, Hande KR, et al. Phase I/II study of SU5416 in combination with irinotecan/5-FU/LV (IFL) in patients with metastatic colorectal cancer [abstract 298]. Proc ASCO 2001;20:75.
156. Rosen PJ, Kabbinavar F, Figlin RA, Parson M, Laxa B, Hernandez L, et al. A phase I/II trial and pharmacokinetic study of SU5416 in combination with paclitaxel/carboplatin [abstract 389]. Proc ASCO 2001;20:98a.
157. Keunen BC, Rosen L, Smit EF, Parson MR, Levi M, Ruijter R, et al. Dose-finding and pharmacokinetic study of cisplatin, gemcitabine, and SU5416 in patients with solid tumors. J Clin Oncol 2002;20:1657-67.
158. Lara PN, Quinn D, Margolin K, Meyers FJ, Longmate J, Frankel P, et al. Angiogenesis inhibition in renal cell carcinoma (RCC): a phase II California Cancer Consortium study of SU5416 + interferon with biologic & imaging correlates [abstract 736]. Proc ASCO 2002;21:185a.
159. Hoekman K. SU6668, a multitargeted angiogenesis inhibitor. Cancer J 2001;7:S134-8.
160. Kuenen B, Ruijter R, Hoekman K, Scigalla P, Giaccone G, Pinedo H. Dose finding study of SU6668 given thrice daily by oral route under fed conditions in patients with advanced malignancies [abstract 437]. Proc ASCO 2002;21:110a.
161. Wood JM, Bold G, Buchdunger E, Cozens R, Ferrari S, Frei J, et al. PTK787/ZK 222584, a novel and potent inhibitor of vascular endothelial growth factor receptor tyrosine kinases, impairs vascular endothelial growth factor-induced responses and tumor growth after oral administration. Cancer Res 2000;60:2178-89.
162. Drevs J, Hofmann I, Hugenschmidt H, Wittig C, Madjar H, Muller M, et al. Effects of PTK787/ZK222584, a specific inhibitor of vascular endothelial growth factor receptor tyrosine kinases, on primary tumor, metastasis, vessel density, and blood flow in a murine renal cell carcinoma model. Cancer Res 2000;60:4819-24.
163. Thomas A, Morgan B, Drevs J, Jivan A, Buchert M, Horsfield M, et al. Pharmacodynamic results using dynamic contrast enhanced magnetic resonance imaging, of 2 phase I studies of the VEGF inhibitor PTK787/ZK222584 in patients with liver metastases from colorectal cancer [abstract 279]. Proc ASCO 2001;20.
164. Drevs J, Mross K, Fuxius S, Müller M, Dugan M, Peng B, et al. A phase I dose-escalating and pharmacokinetic (PK) study of the VEGF-receptor-inhibitor PTK787/ZK222584 (PTK/ZK) in patients with liver metastasis of advanced cancer [abstract 398]. Proc ASCO 2001;20.
165. Togna GI, Togna AR, Franconi M, Caprino L. Cisplatin triggers platelet activation. Thromb Res 2000;99:503-9.
166. Langmuir VK, Cobleigh MA, Herbst RS, Holmgren E, Hurwitz H, Kabbinavar F, et al. Successful long-term therapy with bevacizumab (Avastin) in solid tumors [abstract 32]. Proc ASCO 2002;21:9a.
167. Bowcock SJ, Rassam SM, Ward SM, Turner JT, Laffan M. Thromboembolism in patients on thalidomide for myeloma. Hematology 2002; 7:51-3.